![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LCE3D |
Gene summary for LCE3D |
![]() |
Gene information | Species | Human | Gene symbol | LCE3D | Gene ID | 84648 |
Gene name | late cornified envelope 3D | |
Gene Alias | LEP16 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | Q9BYE3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84648 | LCE3D | C43 | Human | Oral cavity | OSCC | 6.42e-03 | 1.03e+00 | 0.1704 |
84648 | LCE3D | SYSMH3 | Human | Oral cavity | OSCC | 1.48e-35 | 5.76e-01 | 0.2442 |
84648 | LCE3D | SYSMH5 | Human | Oral cavity | OSCC | 2.77e-23 | 6.71e-01 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
GO:00302166 | Oral cavity | OSCC | keratinocyte differentiation | 81/7305 | 139/18723 | 3.16e-06 | 3.81e-05 | 81 |
GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LCE3D | SNV | Missense_Mutation | rs754669874 | c.185N>A | p.Arg62Gln | p.R62Q | Q9BYE3 | protein_coding | tolerated_low_confidence(0.22) | benign(0.024) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LCE3D | SNV | Missense_Mutation | rs199832759 | c.175N>T | p.Arg59Cys | p.R59C | Q9BYE3 | protein_coding | tolerated_low_confidence(0.08) | benign(0.003) | TCGA-ED-A97K-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
LCE3D | SNV | Missense_Mutation | rs201921868 | c.145G>A | p.Glu49Lys | p.E49K | Q9BYE3 | protein_coding | tolerated_low_confidence(0.09) | benign(0.339) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
LCE3D | SNV | Missense_Mutation | c.159N>A | p.Phe53Leu | p.F53L | Q9BYE3 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
LCE3D | SNV | Missense_Mutation | c.76C>A | p.Pro26Thr | p.P26T | Q9BYE3 | protein_coding | tolerated_low_confidence(0.09) | benign(0.021) | TCGA-64-1679-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
LCE3D | SNV | Missense_Mutation | novel | c.68N>A | p.Pro23Gln | p.P23Q | Q9BYE3 | protein_coding | tolerated_low_confidence(0.07) | benign(0.112) | TCGA-78-7148-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
LCE3D | SNV | Missense_Mutation | c.235N>T | p.Gly79Cys | p.G79C | Q9BYE3 | protein_coding | tolerated_low_confidence(0.08) | benign(0.443) | TCGA-66-2734-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LCE3D | SNV | Missense_Mutation | novel | c.70N>C | p.Lys24Gln | p.K24Q | Q9BYE3 | protein_coding | tolerated_low_confidence(0.15) | possibly_damaging(0.824) | TCGA-94-A5I6-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
LCE3D | SNV | Missense_Mutation | rs771339179 | c.107N>T | p.Gly36Val | p.G36V | Q9BYE3 | protein_coding | tolerated_low_confidence(0.17) | benign(0.367) | TCGA-BR-4357-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
LCE3D | SNV | Missense_Mutation | rs775921101 | c.194N>A | p.Arg65His | p.R65H | Q9BYE3 | protein_coding | tolerated_low_confidence(0.17) | benign(0.003) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |